Dallas, TX, United States of America

Verily Life Sciences LLC


USPTO Granted Patents = 967

% Expired Patents = 10.2



Trademarks = 12

Forward Citations = 5,274

Loading Chart...
Loading Chart...

474 inventors (with patents filed for the assignee):

goldMedal Brian Otis (61 out of 90 patents)

silverMedal James Etzkorn (42 out of 56 patents)

bronzeMedal Russell N Mirov (42 out of 73 patents)

4.  William James Biederman (39 out of 47 patents)

5.  Joëlle K Barral (39 out of 39 patents)

6.  Zenghe Liu (37 out of 95 patents)

7.  Eden Rephaeli (35 out of 46 patents)

8.  Stephen O'Driscoll (34 out of 37 patents)

9.  Andrew Homyk (34 out of 43 patents)

10.  Nathan M Pletcher (34 out of 60 patents)

11.  Peter Massaro (33 out of 35 patents)

12.  Anupam J Pathak (32 out of 32 patents)

13.  Supriyo Sinha (32 out of 40 patents)

14.  Shungneng Lee (30 out of 44 patents)

15.  Eric Peeters (30 out of 178 patents)


Core Competencies:
Wearable Devices
Glucose Monitoring
Heart Arrhythmia
Biosensors
Health Monitoring
Neural Interfaces
Ophthalmic Devices
Medical Imaging
Artificial Intelligence
Data Prediction
Surgical Robotics
Patient Monitoring

967 patents:

Verily Life Sciences LLC, based in Dallas, TX, specializes in the development of innovative wearable health technologies aimed at enhancing personal health monitoring. The company focuses on a range of core technology areas, including wearable devices for glucose monitoring, heart arrhythmia detection, and biosensors. Additionally, Verily is engaged in advancing neural interfaces, ophthalmic devices, and medical imaging solutions, contributing to the evolution of healthcare through data-driven insights and improved patient outcomes.
Profile summary based on public USPTO records.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

Verily Life Sciences LLC
967 Patents

#3 in Dallas, TX

#35 in Texas

#536 in US

#1,059 in the World

Dallas, TX (US)
Dallas, TX, United States of America
Forward Citations = 5,274

474 inventors:

Please report any incorrect information to [email protected]
Loading…